Tags

Type your tag names separated by a space and hit enter

Targeting one-carbon metabolism for cancer immunotherapy.
Clin Transl Med. 2024 Jan; 14(1):e1521.CT

Abstract

BACKGROUND

One-carbon (1C) metabolism is a metabolic network that plays essential roles in biological reactions. In 1C metabolism, a series of nutrients are used to fuel metabolic pathways, including nucleotide metabolism, amino acid metabolism, cellular redox defence and epigenetic maintenance. At present, 1C metabolism is considered the hallmark of cancer. The 1C units obtained from the metabolic pathways increase the proliferation rate of cancer cells. In addition, anticancer drugs, such as methotrexate, which target 1C metabolism, have long been used in the clinic. In terms of immunotherapy, 1C metabolism has been used to explore biomarkers connected with immunotherapy response and immune-related adverse events in patients.

METHODS

We collected numerous literatures to explain the roles of one-carbon metabolism in cancer immunotherapy.

RESULTS

In this review, we focus on the important pathways in 1C metabolism and the function of 1C metabolism enzymes in cancer immunotherapy. Then, we summarise the inhibitors acting on 1C metabolism and their potential application on cancer immunotherapy. Finally, we provide a viewpoint and conclusion regarding the opportunities and challenges of targeting 1C metabolism for cancer immunotherapy in clinical practicability in the future.

CONCLUSION

Targeting one-carbon metabolism is useful for cancer immunotherapy.

Links

PMC Free PDF

Authors+Show Affiliations

Ren X
Department of Head and Neck Surgery, Otolaryngology & Head and Neck Center, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, China. Zhejiang Provincial Clinical Research Center for Malignant Tumor, Hangzhou, Zhejiang, China. Department of Pathology, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Wang X
Department of Pharmacy, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Zheng G
Department of Head and Neck Surgery, Otolaryngology & Head and Neck Center, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, China. Zhejiang Provincial Clinical Research Center for Malignant Tumor, Hangzhou, Zhejiang, China.
Wang S
Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Wang Q
Department of Head and Neck Surgery, Otolaryngology & Head and Neck Center, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, China. Zhejiang Provincial Clinical Research Center for Malignant Tumor, Hangzhou, Zhejiang, China.
Yuan M
Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Xu T
Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Xu J
Department of Head and Neck Surgery, Otolaryngology & Head and Neck Center, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, China. Zhejiang Provincial Clinical Research Center for Malignant Tumor, Hangzhou, Zhejiang, China.
Huang P
Department of Pharmacy, Center for Clinical Pharmacy, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Ge M
Department of Head and Neck Surgery, Otolaryngology & Head and Neck Center, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou, Zhejiang, China. Zhejiang Provincial Clinical Research Center for Malignant Tumor, Hangzhou, Zhejiang, China.

MeSH

HumansNeoplasmsAntineoplastic AgentsMetabolic Networks and PathwaysCarbon

Pub Type(s)

Journal Article
Review
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

38279895

Citation

Ren, Xinxin, et al. "Targeting One-carbon Metabolism for Cancer Immunotherapy." Clinical and Translational Medicine, vol. 14, no. 1, 2024, pp. e1521.
Ren X, Wang X, Zheng G, et al. Targeting one-carbon metabolism for cancer immunotherapy. Clin Transl Med. 2024;14(1):e1521.
Ren, X., Wang, X., Zheng, G., Wang, S., Wang, Q., Yuan, M., Xu, T., Xu, J., Huang, P., & Ge, M. (2024). Targeting one-carbon metabolism for cancer immunotherapy. Clinical and Translational Medicine, 14(1), e1521. https://doi.org/10.1002/ctm2.1521
Ren X, et al. Targeting One-carbon Metabolism for Cancer Immunotherapy. Clin Transl Med. 2024;14(1):e1521. PubMed PMID: 38279895.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Targeting one-carbon metabolism for cancer immunotherapy. AU - Ren,Xinxin, AU - Wang,Xiang, AU - Zheng,Guowan, AU - Wang,Shanshan, AU - Wang,Qiyue, AU - Yuan,Mengnan, AU - Xu,Tong, AU - Xu,Jiajie, AU - Huang,Ping, AU - Ge,Minghua, PY - 2023/11/15/revised PY - 2023/08/01/received PY - 2023/12/10/accepted PY - 2024/1/29/medline PY - 2024/1/28/pubmed PY - 2024/1/27/entrez KW - cancer immunotherapy KW - enzymes KW - inhibitors KW - one-carbon metabolism SP - e1521 EP - e1521 JF - Clinical and translational medicine JO - Clin Transl Med VL - 14 IS - 1 N2 - BACKGROUND: One-carbon (1C) metabolism is a metabolic network that plays essential roles in biological reactions. In 1C metabolism, a series of nutrients are used to fuel metabolic pathways, including nucleotide metabolism, amino acid metabolism, cellular redox defence and epigenetic maintenance. At present, 1C metabolism is considered the hallmark of cancer. The 1C units obtained from the metabolic pathways increase the proliferation rate of cancer cells. In addition, anticancer drugs, such as methotrexate, which target 1C metabolism, have long been used in the clinic. In terms of immunotherapy, 1C metabolism has been used to explore biomarkers connected with immunotherapy response and immune-related adverse events in patients. METHODS: We collected numerous literatures to explain the roles of one-carbon metabolism in cancer immunotherapy. RESULTS: In this review, we focus on the important pathways in 1C metabolism and the function of 1C metabolism enzymes in cancer immunotherapy. Then, we summarise the inhibitors acting on 1C metabolism and their potential application on cancer immunotherapy. Finally, we provide a viewpoint and conclusion regarding the opportunities and challenges of targeting 1C metabolism for cancer immunotherapy in clinical practicability in the future. CONCLUSION: Targeting one-carbon metabolism is useful for cancer immunotherapy. SN - 2001-1326 UR - https://www.unboundmedicine.com/medline/citation/38279895/The_Role_of_Diethyl_Malonate_in_Pharmaceutical_Synthesis:_A_Key_Intermediate DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓11 ↑210]

Related Citations

    More

    Others Viewed